Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled study
Yameng Sun(Renji Hospital), Hong You(Harbin Institute of Technology), Yongning Xin(Qingdao University), Cuisong Wu(Jiangsu University), Haixiang Cao(Shenzhen Metro (China)), Junping Shi(Peking University), Yueyong Zhu(Fujian Medical University), Huiying Rao(Peking University), Yuemin Nan(Hebei Medical University), Bihui Zhong(Sun Yat-sen University), Guijie Xin(First Bethune Hospital of Jilin University), Chaohui Yu(First Affiliated Hospital Zhejiang University), Du Jian(Fourth Affiliated Hospital of China Medical University), Zhibin Li(Shanghai Institute of Technology), Yali Liu(Nanjing University of Chinese Medicine), Yue Li(Shanghai University of Traditional Chinese Medicine), Qin Zhang(Shanghai Jiao Tong University), Bo Chen(Craft Group (China)), Jie Xu(Kunming Medical University), Zujiang Yu(First Affiliated Hospital of Zhengzhou University), Huiping Sheng, Xiaoning Wu(First Affiliated Hospital of Xi'an Jiaotong University), Yufeng Gao(Anhui Medical University), Weiwei Sun(Ningbo University), Xiaorong Mao(First Hospital of Lanzhou University), Xiaofei Tong(Capital Medical University), Jia Shang(European Foundation for the Study of Chronic Liver Failure), Xiaofeng Wu(National Clinical Research Center for Digestive Diseases), Lixian Wu(Fujian Medical University)
Cited by 10
Related Papers
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576
New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment
|Hepatology|2016|156
Online Antenatal Care During the COVID-19 Pandemic: Opportunities and Challenges
|Journal of Medical Internet Research|2020|143